Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fitusiran Delay Dents Sanofi’s Hemophilia Challenge

Company Still Aiming For Universal Therapy

Executive Summary

New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.

You may also be interested in...



Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.

Sanofi Hampered By Fitusiran Clinical Hold In Hemophilia

The French major stressed to Scrip that patients enrolled in its fitusiran clinical trials often have other health issues and various co-morbidities, so it is too early to know if the adverse events are treatment-related.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel